Advancing the Science of Concurrent Biologic Therapy
Prospective data on concurrent biologic use remain limited. This registry changes that, aggregating real-world outcomes from published literature and de-identified clinical submissions worldwide to bridge the gap between clinical practice and systematic evidence.
89%
Positive Outcomes
12
Biologic Pairs
17
Diagnoses
The Problem
A Critical Gap in the Evidence Base
There is no shared record of how concurrent biologic therapy performs across specialties. Clinicians decide one case at a time, on partial information.
In clinical practice, a growing number of patients present with overlapping immune-mediated conditions or with disease refractory to single-agent therapy, creating clinical scenarios where concurrent biologic use becomes a consideration. These situations span gastroenterology, rheumatology, dermatology, and other disciplines, yet the evidence base has not kept pace with the clinical need.
Clinicians are left relying on isolated case reports and extrapolation rather than aggregated, systematic data on safety, efficacy, and pharmacologic interactions.
The Solution
The First Registry for Concurrent Biologic Therapy
A centralized, curated repository bridging clinical practice and real-world evidence across immune-mediated inflammatory diseases.
Centralized Evidence
Consolidating cases that would otherwise remain isolated in individual publications or unreported in clinical practice, enabling pattern recognition across a growing body of evidence.
Multi-Center, International
Aggregating real-world data from published literature and clinical submissions across diverse clinical sites globally, reflecting the complexity of actual patient populations.
Toward Consensus
As the evidence base grows, aggregated data from the registry can inform the development of consensus recommendations and best-practice guidance for concurrent biologic prescribing across specialties.
How It Works
A Dual-Source Evidence Model
The registry captures both published evidence and unpublished clinical experience through two complementary data pathways.
Published Literature
Cases documented in peer-reviewed journals, including case reports, case series, and observational studies, are identified, extracted, and catalogued in a standardized format.
Clinical Submissions
Healthcare professionals submit de-identified case data following a structured template that captures only aggregate clinical variables such as age bracket, sex, diagnosis, biologic agents, and outcomes.
Quality Review
Each submission undergoes a structured quality review for completeness, clinical plausibility, and consistency before inclusion in the registry.
Clinical scope
Conditions and biologics
For each case, the registry captures de-identified demographic data (age bracket, sex), the specific biologic agents prescribed, primary diagnosis coded to ICD-10, duration of concurrent therapy, concomitant systemic medications, clinical outcome on a standardized scale, and any adverse events observed during treatment. No personally identifiable health information is collected at any stage.
Conditions in Scope
The registry accepts cases across immune-mediated inflammatory diseases. Examples include:
Biologics in Scope
Submissions may involve any biologic agent, recorded by class or individual molecule. Examples include:
By the Numbers
Registry at a Glance
Real-world evidence from concurrent biologic therapy across published literature and clinical submissions.
Unique Biologic Pairs
Positive Outcomes
Adverse Events Reported
Concomitant Systemic Therapy
Drug Combinations
Biologic Combination Explorer
Patient-level outcome data for each biologic combination can be viewed by selecting a cell.
Biologic combination patient count heatmap
Clinical Outcomes
Treatment Response and Demographics
Outcome categorization and demographic distribution across the registry cohort.
Outcome category
Age distribution
Treatment Patterns
Duration and Prescribing Trends
Duration of concurrent therapy and prescribing frequency across the cohort.
Treatment duration
Most prescribed biologics
Safety Data
Adverse Event Profile
The registry tracks adverse events by sex to identify demographic patterns in safety outcomes. All reported events are captured regardless of severity or attribution.
Adverse events by sex
Independent and open access
No industry funding. No paywalls.
The Concurrent Biologics Registry is provided free of charge to clinicians worldwide and operates without pharmaceutical industry funding or compensation.
Open access
Every dataset, visualization, and analysis is freely available without registration, login, or payment.
Independent
The registry operates fully independently of pharmaceutical companies, drug manufacturers, and trade groups. None influence its scope, methodology, or content.
No industry funding
No pharmaceutical industry funding supports this work. The registry receives no payment, sponsorship, or compensation from drug manufacturers.
Trust and transparency
Built on rigor, designed for openness
The Concurrent Biologics Registry is a freely accessible quality assurance and practice improvement resource. It consolidates published and clinician-submitted evidence into a single repository, lowering the barrier to both contributing and accessing real-world data on concurrent biologic therapy.
De-identified by design
Data collection is structured to capture only aggregate clinical variables, including age band, sex, disease category, biologic agents, and outcomes. Personally identifiable information is never requested, collected, or stored.
Open-access data
The full registry and all visualizations are freely available without registration. No barriers between clinicians and the evidence they need at the point of care.
Structured quality review
Every submitted case undergoes a structured quality review before inclusion, ensuring data quality and clinical accuracy.
Multi-Center Collaboration
Data sourced from published literature and de-identified clinical submissions contributed by clinicians worldwide, reflecting an international collaborative effort.
Common Questions
Frequently Asked Questions
Answers to common questions about the Concurrent Biologics Registry, its data, and how to participate.
Literature
References
10 peer-reviewed sources, 2005–2025
Two Track Biologic Therapy for Concurrent Chronic Spontaneous Urticaria and Psoriasis Vulgaris in One Patient
Benko, M., Hrvatin Stancic, B., & Lunder, T.
Actas Dermo-Sifiliográficas2022113(10), 995–996
Omalizumab and adalimumab: a winning couple
Diluvio, L., Vollono, L., Zangrilli, A., Manfreda, V., Prete, M. D., Massaro, A., Modica, S., Greco, E., Bianchi, L., & Campione, E.
Immunotherapy202012(18), 1287–1292
Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis
Holm, J. G., Sørensen, J. A., & Thomsen, S. F.
International Journal of Dermatology202261(5), e173–e174
Concurrent Atopic Dermatitis and Psoriasis Successfully Treated With Dual Biologic Therapy
Kaszycki, M. A., Pixley, J. N., & Feldman, S. R.
Cutis2023112(3), E13–E16
Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid
Le, S. T., Herbert, S., Haughton, R., Nava, J., Toussi, A., Ji-Xu, A., & Maverakis, E.
JAMA Dermatology2024160(1), 107–109
Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series
Lowes, M. A., Turton, J. A., Krueger, J. G., & Barnetson, R. S.
BMC Dermatology20055(1), Article 9
Is omalizumab safe and effective in oncological patients?
Navarro-Triviño, F. J., Mérida-Fernández, C., Linares-Gonzalez, L., & Ruiz-Villaverde, R.
Dermatologic Therapy201932(6), e13115
Combined use of Omalizumab and dupilumab: safety and efficacy data from a large academic center
Silva, I. C., Daher, R., & Khattri, S.
Archives of Dermatological Research2025317(1), Article 674
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
Thibodeaux, Q., Ly, K., Reddy, V., Smith, M. P., & Liao, W.
JAAD Case Reports20195(10), 928–930
Golimumab in Children with Chronic Recurrent Multifocal Osteomyelitis: A Case Series and Review of the Literature
Yang, C., Rosenwasser, N., Wang, X., Xu, Z., Scheck, J., Boos, M. D., Gupta, D., Brandling-Bennet, H. A., Sidbury, R., Iyer, R. S., & Zhao, Y.
Paediatric Drugs202325(5), 603–611
Contribute
Contribute to the Registry
Clinicians managing patients on concurrent biologic therapy are invited to contribute data. Each submission strengthens the evidence base for concurrent biologic prescribing.
What to Submit
- De-identified patient demographics
- Biologic agents and concurrent therapy details
- Primary diagnosis (ICD-10 coded)
- Duration and clinical outcomes
- Adverse events observed during treatment